Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches
Eric Bui, Franklin King, Andrew Melaragno
General Psychiatry December 1, 2019 DOI: 10.1136/gpsych-2019-100136 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety |
| Keywords | Paradigm shift Pharmacotherapy Psychotherapist Clinical trial Engineering ethics |
| Citations | 14 |
| Key findings | Novel molecular pathways for treating anxiety and stress-related disorders are under investigation, and combining pharmacotherapy with psychotherapy may introduce a paradigm shift in psychiatric care. |
Abstract
While limited advances have occurred in the past 30 years in the pharmacological management of anxiety and stress-related disorders, novel molecular pathways both within and without the monoamine systems are currently under investigation and offer promising new avenues for more effective future treatments. Enhancing psychotherapy approaches with pharmacological compounds offers the potential to not only transform the standard of care of these conditions, but more broadly would introduce a paradigm shift in the way medications and their role in psychiatric care are conceptualised. Although further human trials and more translational research are sorely needed, continuing to pursue innovative mechanisms and treatments is hoped to yield substantial results in the coming decades and a departure from the reliance on chemical agents of the 20th century.
Comparable studies
Other narrative reviews on anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Mindfulness-based interventions: an overall review General (healthcare, schools, workplace) | 2021 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement | |
| Sudarshan Kriya Yogic Breathing in the Treatment of Stress, Anxiety, and Depression: Part II—Clinical Applications and Guidelines | 2005 | Review | |
| Mindfulness Meditation and Psychopathology | 2018 | Review | |
| Management of Treatment-Resistant Depression: Challenges and Strategies | 2020 | Review |
Citations in the library
Cited by 3
- Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field. FOCUS: The Journal of Lifelong Learning in Psychiatry June 17, 2020
- Expanded access to psychedelic treatments: comparing American and Canadian policies. General Psychiatry February 19, 2025
- Pharmaco-Analysis of Psychedelics—Philo-Fictions about New Materialism, Quantum Mechanics, Information Science, and the Philosophy of Immanence Philosophies December 30, 2023
Cites 30
- Using Self-Report Assessment Methods to Explore Facets of Mindfulness Assessment January 27, 2006
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
and 25 more in the library